Yechezkel Barenholz

Yechezkel Barenholz, PhD


Professor Yechezkel (Chezy) Barenholz is a professor emeritus of biochemistry and cancer research at the Hebrew University‐Hadassah Medical School, Jerusalem, and a recognized expert in the field of drug delivery. He is the author of over 430 publications many of which are widely cited.

Professor Barenholz is a co-inventor of over 55 patent families including being one of the major inventors of Doxil® (pegylated nano-liposomes remote loaded with the anticancer drug doxorubicin for cancer treatment. Doxil® is the first nano-drug approved by FDA as well as being the first liposomal drug approved by the FDA. Doxil® was marketed in the US by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). Now it is marketed by Baxter. Over 1,000,000 cancer patients are treated so-far globally with Doxil or its four generic versions.

Prof. Barenholz is founder of several prominent startup companies, including; Ayana Pharma Ltd that under his guidance achieved FDA approval of one of the 4 versions of FDA approved generic Doxil, now sold in the USA as well as the clinical stage Moebius Medical Ltd.